Rationale and design of the RESTORE trial: A multicenter, randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu injection on myocardial injury in STEMI patients after primary PCI.
Xiao WangRuifeng GuoYingying GuoQian GuoYan YanWei GongWen ZhengHui WangLei XuHui AiBin QueXiaoyan YanXinliang MaShaoping NiePublished in: American heart journal (2023)
The RESTORE trial is sufficiently powered to demonstrate the clinical effects of Shenfu injection on myocardial injury in STEMI patients undergoing PPCI in the contemporary era.
Keyphrases
- phase iii
- double blind
- phase ii
- percutaneous coronary intervention
- study protocol
- patients undergoing
- clinical trial
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- end stage renal disease
- placebo controlled
- open label
- ejection fraction
- chronic kidney disease
- acute myocardial infarction
- prognostic factors
- acute coronary syndrome
- ultrasound guided
- randomized controlled trial
- peritoneal dialysis
- antiplatelet therapy
- heart failure
- left ventricular
- coronary artery bypass grafting